Patients hospitalized with active cancer are more likely to die from COVID-19

New research indicates that patients hospitalized with active cancer were more likely to die from COVID-19 than those with a history of cancer or those without any cancer diagnosis.

The findings published by Wiley early online in CANCER, a peer-reviewed journal of the American Cancer Society, also indicate those with active blood cancers have the greatest risk of death due to COVID-19. Researchers found no increased mortality risk in patients who received cancer treatments in the three months (or longer) prior to hospitalization.

To investigate how cancer, or the various therapies used to treat it, can affect the health of patients who develop COVID-19, a team analyzed the NYU Langone Medical Center's records of 4,184 hospitalized patients who tested positive for SARS-CoV-2, the virus that causes COVID-19.

This group included 233 patients with a current, or "active," cancer diagnosis. More patients with an active cancer diagnosis (34.3 percent) were likely to die from COVID-19 than those with a history of cancer (27.6 percent) and those without any cancer history (20.0 percent).

Among patients with active cancer, those with blood-related cancers were at the highest risk of death. Receiving systemic anticancer therapy, including chemotherapy, molecularly targeted therapies, and immunotherapy, within three months prior to hospitalization was not linked to a higher risk of death, and the investigators found no differences based on the types of cancer therapy received.

We completed a large chart review-based study of patients hospitalized with COVID-19 and found that patients with active cancer, but not a history of cancer, were more likely to die. Notably, however, among those hospitalized with active cancer and COVID-19, recent cancer therapy was not associated with worse outcomes. People with active cancer should take precautions against getting COVID-19, including vaccination, but need not avoid therapy for cancer."

Daniel Becker, MD, Study Senior Author

CANCER’s incoming Editor-in-Chief Suresh S. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University and assistant dean for cancer research at Emory University School of Medicine, noted that the findings highlight the importance of COVID-19 vaccination for individuals with cancer.

Journal reference:

Fu, C., et al. (2021) COVID-19 outcomes in hospitalized patients with active cancer: Experiences from a major New York City health care system. Cancer.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Researchers develop 3D organoid model to advance understanding of gastroesophageal junction cancer